Eylea

Roche’s new eye drug pressures Eylea with strong launch
Roche’s new eye drug pressures Eylea with strong launch
BioPharma Dive
Roche
Vabysmo
Eylea
earnings
Regeneron
Flag link:
5 FDA decisions to watch in the second quarter
5 FDA decisions to watch in the second quarter
BioPharma Dive
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biogen
tofersen
ALS
Seres Therapeutics
C. difficile
Pfizer
GSK
vaccines
RSV
Regeneron
Eylea
Flag link:
Bayer grapples with Eylea sales slowdown, sees trend continuing in 2023
Bayer grapples with Eylea sales slowdown, sees trend continuing in 2023
Fierce Pharma
Bayer
earnings
Eylea
Flag link:
In showdown with Roche, Regeneron gears up for potential Eylea expansion amid Covid decline
In showdown with Roche, Regeneron gears up for potential Eylea expansion amid Covid decline
Endpoints
Regeneron
earnings
Eylea
Flag link:
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
Endpoints
Regeneron
Novartis
Eylea
drug delivery
patents
Lucentis
Flag link:
Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar
Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar
Endpoints
Coherus Biosciences
biosimilars
ophthalmology
Eylea
Regeneron
Flag link:
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Fierce Pharma
Roche
Genentech
Vabysmo
bispecific antibodies
Eylea
Flag link:
Regeneron, Bayer's Eylea nabs six months of pediatric exclusivity as competition waits to enter the market
Regeneron, Bayer's Eylea nabs six months of pediatric exclusivity as competition waits to enter the market
Endpoints
Regeneron
Bayer
Eylea
pediatric exclusivity
biosimilars
Flag link:
Regeneron secures priority review for Eylea's use in infant retinopathy
Regeneron secures priority review for Eylea's use in infant retinopathy
Fierce Pharma
Eylea
Regeneron
retinopathy of prematurity
FDA
priority review
Flag link:
Bayer, Regeneron's eye drug shown to work at higher dose, longer intervals
Bayer, Regeneron's eye drug shown to work at higher dose, longer intervals
Yahoo/Reuters
Bayer
Regeneron
Eylea
diabetic macular edema
wet age-related macular degeneration
Flag link:
Kodiak matches Regeneron’s Eylea in macular edema phase 3, lighting Beacon of hope after flop
Kodiak matches Regeneron’s Eylea in macular edema phase 3, lighting Beacon of hope after flop
Fierce Biotech
Kodiak Sciences
Regeneron
Bayer
Eylea
macular edema
clinical trials
tarcocimab
Flag link:
Regeneron's Dupixent and Eylea Offset Drop in COVID-19 Antibody Sales
Regeneron's Dupixent and Eylea Offset Drop in COVID-19 Antibody Sales
BioSpace
Regeneron
earnings
COVID-19
Eylea
Dupixent
Flag link:
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Fierce Pharma
Regeneron
Eylea
Roche
Vabysmo
Flag link:
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
BioSpace
Alvotech
AVT06
biosimilars
clinical trials
Eylea
Flag link:
Regeneron's Eylea could lose 30% of its patients to Roche's Vabysmo over the next year: analyst survey
Regeneron's Eylea could lose 30% of its patients to Roche's Vabysmo over the next year: analyst survey
Fierce Pharma
Regeneron
Eylea
Vabysmo
Roche
wet-AMD
Flag link:
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
Motley Fool
Regeneron
patents
patent cliff
Eylea
Flag link:
With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?
With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?
Fierce Pharma
Bayer
Eylea
Xarelto
drug launches
Flag link:
Kodiak's Eylea rival hits 'major disappointment' with failure in first of 6 phase 3 studies
Kodiak's Eylea rival hits 'major disappointment' with failure in first of 6 phase 3 studies
Fierce Biotech
Kodiak Sciences
KSI-301
Eylea
Bayer
Regeneron
Flag link:
Roche pharma CEO Anderson talks up Vabysmo’s 'very strong launch' plans as Eylea battle looms
Roche pharma CEO Anderson talks up Vabysmo’s 'very strong launch' plans as Eylea battle looms
Fierce Pharma
Roche
Vabysmo
drug launches
Bill Anderson
Eylea
Flag link:
Roche grabs FDA okay for would-be blockbuster eye drug faricimab
Roche grabs FDA okay for would-be blockbuster eye drug faricimab
Pharmaforum
Roche
faricimab
Eylea
Bayer
Regeneron
FDA
Flag link:

Pages